In this review, we discuss biomarker-directed treatment for breast cancer, mechanisms of resistance to CDK4/6 inhibitors, and attempts to uncover ctDNA liquid biopsy biomarkers of efficacy and resistance to CDK4/6 inhibitors. The gene discussed is CDK4; the disease is breast carcinoma.